TTRAIL · Transferable Trustworthy Radiotherapy with Artificial Intelligence

Lines connect the coordinator with its partners. CORDIS does not always give exact coordinates for projects before 2014. These points are placed at city or country level.

Project objective

Cancer is the leading cause of death in Europe and the second worldwide. Over 50% of patients are treated with Radiotherapy (RT) and it accounts for 40% of cures, yet recurrence and toxicities remain significant challenges. Despite major advances in imaging, planning and delivery, RT still largely follows a “one-dose-fits-all” approach, leading to variable outcomes, toxicities and limited adaptability to patient-specific biology. Europe is currently undergoing a digital transformation driven by AI, advanced imaging and the European Health Data Space, but current AI solutions in RT remain fragmented, poorly generalizable and insufficiently explainable, preventing their safe deployment in clinical practice. TTRAIL aims at improving the safety, precision and personalization of radiotherapy (RT) by training 15 Doctoral Candidates as the first generation of Translational AI Radiotherapy Scientists, capable of uniting AI innovation with clinical radiotherapy, medical physics, regulatory science and digital-health translation. Their training will span multiscale data integration, uncertainty quantification, explainable and causal outcome modelling, digital twins and real-time adaptive dose delivery, aligned with the EU AI Act.The consortium unites top European universities, engineering schools, cancer centers and major industrial partners, providing access to cutting-edge RT platforms, large multicentre datasets and expertise across AI, imaging, oncology, physics and regulatory compliance. This intersectoral ecosystem ensures robust scientific training, clinical immersion, industrial exposure and strong open-science practices.By delivering a fully integrated, trust-by-design framework for AI-enabled Adaptive Radiotherapy, TTRAIL will produce highly skilled researchers able to lead the future of personalised, safe and explainable cancer treatment in Europe.

Original text from CORDIS.

Participants

• UNIVERSITE DE RENNES · RennesCoordinatorFrance
• BRAINLAB SE · MUNCHENGermany
• CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE BREST · BrestFrance
• Centre Eugène Marquis · RennesCity levelFrance
• DASSAULT SYSTEMES · VELIZY VILLACOUBLAYFrance
• ECOLE CENTRALE DE NANTES · Nantes Cedex 3France
• EMPRESA DE BASE TECNOLOGICA INTERNACIONAL DE CANARIAS, SOCIEDAD LIMITADA · LAS PALMAS DE GRAN CANARIACity levelSpain
• EURECOM GIE · BiotFrance
• FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI · MilanItaly
• IDCQ HOSPITALES Y SANIDAD SL · MadridSpain
• INSTITUT MINES-TELECOM · PalaiseauFrance
• INSTITUTO TECNOLOGICO METROPOLITANO · MedellinColombia
• KARLSRUHER INSTITUT FUER TECHNOLOGIE · KarlsruheGermany
• KIWA NEDERLAND BV · ApeldoornNetherlands
• OSPEDALE SAN RAFFAELE SRL · MilanoItaly
• PANEPISTIMIO PATRON · RIO PATRASGreece
• POLITECNICO DI MILANO · MilanoItaly
• SIEMENS HEALTHCARE SL · MADRIDSpain
• SORBONNE UNIVERSITE · ParisFrance
• THE UNIVERSITY OF MANCHESTER · ManchesterUnited Kingdom
• UNICANCER · ParisFrance
• UNIVERSIDAD CARLOS III DE MADRID · Getafe (Madrid)Spain
• UNIVERSIDAD REY JUAN CARLOS · MostolesSpain
• UNIVERSITAET BERN · BernSwitzerland

Links

• View on CORDIS
• DOI: 10.3030/101312626